Keith Gottesdiener

11.6k total citations · 2 hit papers
127 papers, 7.6k citations indexed

About

Keith Gottesdiener is a scholar working on Molecular Biology, Pharmacology and Epidemiology. According to data from OpenAlex, Keith Gottesdiener has authored 127 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 36 papers in Pharmacology and 32 papers in Epidemiology. Recurrent topics in Keith Gottesdiener's work include Inflammatory mediators and NSAID effects (22 papers), Trypanosoma species research and implications (20 papers) and Pharmacogenetics and Drug Metabolism (12 papers). Keith Gottesdiener is often cited by papers focused on Inflammatory mediators and NSAID effects (22 papers), Trypanosoma species research and implications (20 papers) and Pharmacogenetics and Drug Metabolism (12 papers). Keith Gottesdiener collaborates with scholars based in United States, United Kingdom and Belgium. Keith Gottesdiener's co-authors include John A. Wagner, Jeffrey Chodakewitz, Patrick Larson, M. Juliana McElrath, Ann Duerr, Danilo R. Casimiro, Susan Buchbinder, Peter B. Gilbert, Michael Robertson and Lawrence Corey and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Keith Gottesdiener

127 papers receiving 7.3k citations

Hit Papers

2 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

2008 1.2k citations Keith Gottesdiener et al. profile →
Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist

2016 309 citations Keith Gottesdiener et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Keith Gottesdiener United States	47	2.1k	1.8k	1.2k	1.1k	1.1k	127	7.6k
Patricia E. Molina United States	37	2.0k 0.9×	1.4k 0.8×	575 0.5×	718 0.6×	828 0.7×	250	7.8k
Jean‐Philippe Bastard France	35	1.4k 0.7×	3.0k 1.7×	1.1k 0.9×	268 0.2×	2.3k 2.1×	100	7.0k
Cristóbal Richart Spain	42	1.4k 0.6×	2.6k 1.5×	829 0.7×	282 0.2×	1.5k 1.4×	216	6.5k
Judy K. Shigenaga United States	40	2.0k 0.9×	1.3k 0.7×	856 0.7×	185 0.2×	748 0.7×	65	5.8k
Jeremy B. M. Jowett Australia	36	2.5k 1.2×	1.7k 0.9×	332 0.3×	320 0.3×	1.1k 1.0×	70	6.3k
Jordi Camps Spain	46	1.4k 0.7×	1.7k 1.0×	794 0.7×	804 0.7×	628 0.6×	252	7.1k
Juan V. Esplugues Spain	43	1.8k 0.8×	825 0.5×	227 0.2×	383 0.3×	1.5k 1.3×	229	6.3k
Christoph Ebenbichler Austria	45	998 0.5×	1.8k 1.0×	1.1k 0.9×	274 0.2×	1.9k 1.7×	138	6.1k
Yong Huang China	48	1.8k 0.9×	839 0.5×	343 0.3×	307 0.3×	428 0.4×	167	7.2k
Nobuyuki Kobayashi Japan	44	2.0k 0.9×	1.2k 0.7×	240 0.2×	240 0.2×	593 0.5×	315	7.1k

Countries citing papers authored by Keith Gottesdiener

Since Specialization

Citations

This map shows the geographic impact of Keith Gottesdiener's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith Gottesdiener with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith Gottesdiener more than expected).

Fields of papers citing papers by Keith Gottesdiener

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith Gottesdiener. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith Gottesdiener. The network helps show where Keith Gottesdiener may publish in the future.

Co-authorship network of co-authors of Keith Gottesdiener

This figure shows the co-authorship network connecting the top 25 collaborators of Keith Gottesdiener. A scholar is included among the top collaborators of Keith Gottesdiener based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith Gottesdiener. Keith Gottesdiener is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Kong Y., Ranganath Muniyappa, Brent S. Abel, et al.. (2015). RM-493, a Melanocortin-4 Receptor (MC4R) Agonist, Increases Resting Energy Expenditure in Obese Individuals. The Journal of Clinical Endocrinology & Metabolism. 100(4). 1639–1645. 135 indexed citations

Simon, James A., Julie Chandler, Keith Gottesdiener, et al.. (2014). Diary of hot flashes reported upon occurrence. Menopause The Journal of The North American Menopause Society. 21(9). 938–944. 15 indexed citations

Shin, Andrea, Michael Camilleri, Irene Busciglio, et al.. (2012). Randomized Controlled Phase Ib Study of Ghrelin Agonist, RM-131, in Type 2 Diabetic Women With Delayed Gastric Emptying. Diabetes Care. 36(1). 41–48. 85 indexed citations

Iannone, Raffaele, B.R. Bloem, John Palcza, et al.. (2011). The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol. Journal of Psychopharmacology. 26(2). 292–302. 16 indexed citations

Herman, Gary, Goutam C. Mistry, Bingming Yi, et al.. (2010). Evaluation of pharmacokinetic parameters and dipeptidyl peptidase‐4 inhibition following single doses of sitagliptin in healthy, young Japanese males. British Journal of Clinical Pharmacology. 71(3). 429–436. 29 indexed citations

Mistry, Goutam C., Arthur Bergman, Wei Zheng, et al.. (2008). Sitagliptin, an dipeptidyl peptidase‐4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. British Journal of Clinical Pharmacology. 66(1). 36–42. 42 indexed citations

Lepeleire, Inge De, Carol Addy, Paul Rothenberg, et al.. (2007). Brain CB-1 receptor occupancy of taranabant in lean subjects using CB-1R PET. Diabetologia. 50. 1 indexed citations

Erondu, Ngozi, Carol Addy, Kaifeng Lu, et al.. (2007). NPY5R Antagonism Does Not Augment the Weight Loss Efficacy of Orlistat or Sibutramine. Obesity. 15(8). 2027–2042. 23 indexed citations

Malmström, Kerstin, Paul Kotey, Rohini Ramakrishnan, et al.. (2006). Dental Impaction Pain Model as a Potential Tool to Evaluate Drugs With Efficacy in Neuropathic Pain. The Journal of Clinical Pharmacology. 46(8). 917–924. 4 indexed citations

10.

Cheng, Kang, Tsuei-Ju Wu, Kenneth K. Wu, et al.. (2006). Antagonism of the prostaglandin D ₂ receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proceedings of the National Academy of Sciences. 103(17). 6682–6687. 222 indexed citations

11.

Nygren, Peter, Kenneth R. Hande, Kevin J. Petty, et al.. (2005). Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemotherapy and Pharmacology. 55(6). 609–616. 56 indexed citations

12.

Agrawal, Nancy, Catherine Z. Matthews, Ralph S. Mazenko, et al.. (2003). Pharmacokinetics of Etoricoxib in Patients with Renal Impairment. The Journal of Clinical Pharmacology. 44(1). 48–58. 32 indexed citations

13.

Wagner, John, Jody C Miller, Dominique Ballaux, et al.. (2003). Single and Multiple Doses of MK-0767 (KRP-297) reduce Free Fatty Acids (FFA) and Lipids in Healthy Subjects.. Diabetes. 52. 1 indexed citations

14.

Rodrigues, A. David, Rita A. Halpin, Leslie A. Geer, et al.. (2003). Absorption, Metabolism, and Excretion of Etoricoxib, a Potent and Selective Cyclooxygenase-2 Inhibitor, in Healthy Male Volunteers. Drug Metabolism and Disposition. 31(2). 224–232. 64 indexed citations

15.

Larsen, Thomas Meinert, Søren Toubro, Marleen A. van Baak, et al.. (2002). Effect of a 28-d treatment with L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure and body composition in obese men. American Journal of Clinical Nutrition. 76(4). 780–788. 137 indexed citations

16.

Gottesdiener, Keith, Clare T. Atherton, Barry J. Gertz, et al.. (2001). Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. Gastroenterology. 120(4). 867–873. 49 indexed citations

17.

Wagner, John A., Walter K. Kraft, Joanne Burke, et al.. (2001). THE COX-2 INHIBITOR ETORICOXIB DID NOT ALTER THE ANTI-PLATELET EFFECTS OF LOW-DOSE ASPIRIN IN HEALTHY VOLUNTEERS.. Arthritis & Rheumatism. 44(9). 5 indexed citations

18.

Gottesdiener, Keith, Donald R. Mehlisch, Martha Huntington, et al.. (1999). Efficacy and tolerability of the specific cyclooxygenase-2 inhibitor DFP compared with naproxen sodium in patients with postoperative dental pain. Clinical Therapeutics. 21(8). 1301–1312. 21 indexed citations

19.

Ploeg, Lex H.T. Van der, Cassandra L. Smith, Ramona I. Polvere, & Keith Gottesdiener. (1989). Improved separation of chromosome-sized DNA fromTrypanosoma brucei, stock 427-60. Nucleic Acids Research. 17(8). 3217–3227. 68 indexed citations

20.

Rauh, W, et al.. (1980). Aldosterone Response to Prolonged ACTH Infusion in Juvenile Hypertension. Pediatric Research. 14(9). 1035–1039. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact